New stock news: Ke Li Port stock IPO prospectus invalid.
KeLi Limited Company (referred to as "KeLi")'s Hong Kong stock prospectus submitted on December 18, 2025, expired after 6 months on June 18, 2026.
Koli Corporation Limited (referred to as Koli) submitted its Hong Kong stock prospectus on December 18, 2025, which expired after 6 months on June 18, 2026, with CICC as its exclusive sponsor at the time of submission.
According to the prospectus, Koli is a comprehensive medical health solution provider originating from South Korea, with its main business located in China and expanding internationally. According to data from Frost & Sullivan, based on revenue in 2024, the company ranks among the top ten in marketing, promotion, and sales markets within China Meheco Group. Based on revenue in 2024, the company is the largest pediatric pharmaceutical marketing, promotion, and sales service provider in China, accounting for approximately 15.9% of the market share in China.
Related Articles
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
RECOMMEND
